1,634 material Form 8-K filings that 1,408 companies we cover made with the SEC in November 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). 591 of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Innovative Industrial Properties amended its equity distribution agreements to add its 9.25% Series B Cumulative Redeemable Preferred Stock to its at-the-market offering program, alongside common stock and 9.00% Series A Preferred Stock. About $336.9 million of the program's $500 million capacity remained available as of the filing date, which gives the company a path to issue more shares that could dilute existing holders.
Program covers common stock, Series A Preferred Stock and Series B Preferred Stock, with aggregate offering price of up to $500 million
Approximately $336.9 million remained available for sale under the ATM Prospectus Supplement dated November 9, 2026
Amendments were entered into November 9, 2026 with BTIG, Piper Sandler, Roth Capital, Stifel, A.G.P./Alliance Global Partners and Huntington Securities
SS&C Technologies completed a private offering of $1.2 billion of 2.75% convertible senior notes due December 1, 2031, including a $150 million option exercised in full by the initial purchasers. The company plans to use the proceeds for capped call transactions, share repurchases of about $100 million, and redeeming its $2.0 billion of 5.500% Senior Notes due 2027, which adds debt and creates potential dilution if the notes convert.
Notes issued November 6, 2026 under an indenture with Wilmington Trust, National Association, as trustee, bearing interest at 2.75% payable June 1 and December 1.
Initial conversion price of about $99.46 per share, a premium of about 25.0% over the $79.57 closing price on November 4, 2026.
Proceeds planned for about $99 million capped call cost, about $100 million of share repurchases (about 1.3 million shares), and redemption of the $2,000.0 million 2027 Senior Notes.
Company may not redeem the notes before December 5, 2029, except in a cleanup redemption.
Sonoco said CEO R. Howard Coker will retire as director, president and chief executive officer effective December 31, 2026. The board named Ernest D. Haynes III, the company's president of Global Consumer Packaging, to succeed him as CEO and as a director on that date.
Coker's retirement is effective December 31, 2026; the board accepted his notice dated November 6, 2026.
Haynes, who joined Sonoco in 1997, has an annual base salary of $1,100,004 and a bonus target of 120% of salary.
CFO Paul Joachimczyk received a $1,500,000 restricted stock unit retention award that cliff vests on the second anniversary of the grant date.
Sonoco leadership, including Coker, Haynes and Joachimczyk, will present at an R.W. Baird conference webcast on November 10, 2026, starting 7:20 a.m. Central Time.
Aptevo Therapeutics reported on November 9, 2026 that it presented new preclinical data from its next-generation multispecific platform at the SITC 2026 Annual Meeting on November 7, 2026. The lab results cover APVO451, APVO452 and APVO711, which the company says showed tumor-cell killing and immune activation under conditions that suppress immune responses. The filing contains no financial results, and the data are early-stage, so the update does not change reported financials.
Presentation made on November 7, 2026 at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting.
APVO451 and APVO452 showed tumor-cell killing and T-cell activation under immunosuppressive conditions in preclinical studies.
APVO711 combined CD40 activation with PD-L1 checkpoint blockade in preclinical findings.
APVO451 and APVO452 are expected to advance into IND-enabling studies in 2027.
Newell Brands expanded its board from eight to nine members and elected William "Bill" Newlands as a director, effective January 1, 2027. Newlands previously served as President and CEO of Constellation Brands from 2019 to April 2026, and the filing says his experience in consumer brand strategy and capital allocation will be valuable to the company.
Board size increases from eight to nine members; Newlands' election takes effect January 1, 2027.
Newlands will serve on the Audit Committee and the Compensation and Human Capital Committee from January 1, 2027.
Newlands will receive the same compensation as the company's other non-employee directors, per the March 26, 2026 proxy statement.
Filing states there are no arrangements under which he was selected and no reportable related-party transactions.
Vistagen reported constructive FDA feedback from a Type C meeting on registrational paths for its lead product candidate, fasedienol, in social anxiety disorder. The company plans to use interim assessments, submit a revised protocol, and focus development on the general SAD population rather than acute treatment alone.
FDA gave constructive feedback on using the Liebowitz Social Anxiety Scale as the primary endpoint in a future Phase 3 study.
Vistagen plans to add interim assessments using eDiaries and qualitative patient surveys and to submit a revised protocol to the FDA.
The company plans to pursue fasedienol for overall, not only acute, treatment of SAD, and cited the FDA's recognition of its reported safety profile.
The filing contains no financial results, and the company states that future FDA feedback may not lead to a successful registrational pathway.
Vir Biotechnology said its pivotal Phase 3 ECLIPSE 1 trial of elebsiran and tobevibart in adults with chronic hepatitis delta met its primary and key secondary endpoints, with data presented at the AASLD Liver Meeting on November 8, 2026. The company also released expanded Phase 2 SOLSTICE data and preliminary, exploratory findings on treatment discontinuation, which the company itself says are interim and not a complete assessment of safety or efficacy.
ECLIPSE 1 primary endpoint: 44% of patients on elebsiran and tobevibart reached undetectable virus plus ALT normalization at Week 48, versus 0% in the delayed treatment group at Week 12 (p<0.0001)
Key secondary endpoint: 79% reached undetectable virus at Week 48, versus 0% in the delayed treatment group
SOLSTICE Week 96: 100% (28/28) of patients who completed Week 96 of combination therapy reached undetectable viremia
Exploratory analysis: 10 patients discontinued treatment; all 10 achieved SVR12, with 7 reaching SVR24 and 1 reaching SVR48; the filing states these data are preliminary and not a claim of cure
Empery Digital said on November 9, 2026 that it and Hunt Properties continue lease negotiations for the Midwest AI data center facility and expect to execute a lease in the near term. The definitive agreement to purchase the property has been amended and extended, and the company repurchased 155,040 shares in the week ended November 6, 2026, leaving approximately $49 million under its $200 million buyback authorization.
No lease has been executed yet; the company expects to execute one in the near term
Purchase agreement for the Midwest facility amended and extended while lease talks continue
Repurchased 155,040 shares in the week ended November 6, 2026 at an average of $2.36 per share
Aggregate repurchases reached 26,686,348 shares; about $49 million remains under the $200 million program
OneMedNet said year-to-date bookings reached approximately $18.76 million as of November 6, 2026, with $1.388 million converted to revenue through September 30, 2026. The company also reported that contracted demand is nearly 14 times its full-year 2025 bookings and that roughly half of its 2026 contracts come from new customers, while providing fourth-quarter 2026 guidance without figures in the filing text.
Year-to-date bookings: approximately $18.76 million as of November 6, 2026
Revenue converted from bookings: $1.388 million through September 30, 2026
Contracted demand is nearly 14 times full-year 2025 bookings
Roughly half of 2026 contracts are from new customers
Super League Enterprise disclosed that from November 4 through November 9, 2026, it purchased sixteen Bitcoin at an average price of approximately $76,892.32 per Bitcoin. The company said the purchases are part of its exploration of Bitcoin as a treasury asset alongside cash and cash equivalents. The filing is limited to this purchase and does not report financial results or guidance.
Purchased 16 Bitcoin between November 4, 2026 and November 9, 2026
Average purchase price of approximately $76,892.32 per Bitcoin
Company describes the buys as part of exploring Bitcoin as a treasury asset alongside cash and cash equivalents
Neurogene Inc. reported third quarter 2026 results, with a net loss of $29.0 million for the three months ended September 30, 2026, up from $21.0 million a year earlier. Higher R&D and G&A spending, driven largely by NGN-401 development and stock-based compensation, drove the increase, and the company said its cash position is expected to fund operations into the first quarter of 2029.
Net loss was $29.0 million for Q3 2026, compared with $21.0 million for Q3 2025.
R&D expenses rose to $23.5 million from $17.2 million, mainly for NGN-401 clinical trial and manufacturing activities.
G&A expenses rose to $8.9 million from $6.6 million, mainly from higher non-cash stock-based compensation.
Cash, cash equivalents and short-term investments were $359.7 million as of September 30, 2026, expected to fund operations into the first quarter of 2029.
Safe Harbor reported third-quarter 2026 revenue of $1.95 million, up 6.5%, while swinging to a net loss of approximately $979,000 from net income a year earlier that included a $3.34 million debt extinguishment gain. The company also disclosed a nonbinding term sheet with Opifex Media Inc. under which Opifex security holders would own about 85% of the combined company, and the company's common share count rose sharply after Series B conversions, which shareholders should weigh against these results.
Q3 2026 revenue was $1.95 million, up from $1.83 million; net loss was approximately $979,000, or $0.95 per share, versus net income of approximately $180,000 in Q3 2025.
Nonbinding term sheet with Opifex Media Inc. signed October 23, 2026; Opifex holders would own approximately 85% of the combined company's fully diluted shares, with the Safe Harbor share adjustable from 12.5% to 17.5%.
Series B conversion price reset to $0.1210 on October 22, 2026; common shares outstanding rose from 1,028,702 on September 30 to 132,248,520 on November 6, 2026.
Nasdaq granted an additional period through April 19, 2027 to regain compliance with the $1 minimum bid price; cash was $4.4 million at September 30, 2026, and the filing includes a going concern disclosure.
DeFi Development Corp. (DFDV) reported in a Form 8-K that its SOL and SOL equivalent holdings rose by 8,881 between November 2 and November 6, 2026, to 2,609,829, up from 2,600,948 as of October 30. The company said it expects treasury SOL to be deployed through its staking, validator and onchain treasury infrastructure, subject to market conditions and risk management. The filing is a routine holdings update that includes no earnings or financial results.
SOL and SOL equivalents rose from 2,600,948 on October 30, 2026 to 2,609,829 on November 6, 2026.
The November 9, 2026 press release says this is the ninth consecutive week of SOL purchases, starting September 14, 2026.
The company's Variable Rate Series C Perpetual Preferred Stock (CHAD) carries a 14.00% annualized dividend rate on a $10.00 stated amount, or $1.40 per share annually.
The company's risk factors note that SOL price declines could cause losses and that CHAD dividends are payable only when declared.
Heron Therapeutics reported third-quarter 2026 net revenue of $35.3 million, down 7.8% from $38.2 million a year earlier, while its net loss narrowed to $5.0 million from $17.5 million. The same day, Heron agreed to sell substantially all of its assets to CorMedix Therapeutics, a deal that requires Heron stockholder approval, and the company is not providing 2026 financial guidance.
Q3 2026 net revenue was $35.3 million, compared with $38.2 million in Q3 2025 and $37.7 million in Q2 2026.
Q3 2026 net loss was $5.0 million, compared with $17.5 million in Q3 2025.
CorMedix Therapeutics will acquire substantially all of Heron's assets under a definitive asset purchase agreement, subject to Heron stockholder approval and other closing conditions.
Heron withdrew its full-year 2026 guidance in August 2026 and is not providing guidance at this time; cash and short-term investments were $23.4 million at September 30, 2026.
Mereo BioPharma reported a third-quarter 2026 net loss of $5.9 million, down from $7.0 million a year earlier, as research and development and general and administrative expenses fell and the company recorded $800 thousand of revenue versus none a year earlier. Cash and cash equivalents were $26.1 million at September 30, 2026, which the company says should fund operations into late 2027, excluding any potential option payments from Sentynl Therapeutics.
Q3 2026 net loss was $5.9 million, compared with $7.0 million in Q3 2025; nine-month net loss was $19.6 million versus $34.5 million a year earlier.
Q3 2026 revenue was $800 thousand, compared with no revenue in Q3 2025; R&D expenses fell to $2.1 million from $4.3 million and G&A expenses fell to $4.9 million from $6.0 million.
Cash and cash equivalents were $26.1 million at September 30, 2026, down from $41.0 million at December 31, 2025.
Sentynl's exercise of its alvelestat option would bring $40 million in upfront and R&D payments; Mereo expects to provide an FDA-related update before the end of 2026.
OPAL Fuels reported third quarter 2026 revenue of $79.5 million, down 5% from a year earlier, while Adjusted EBITDA rose 32% to $26.7 million and net income was $1.7 million versus a $1.9 million loss. The company now expects 2026 RNG production to be modestly below its guidance range and expects full-year Adjusted EBITDA at the lower end of its guidance range, which it maintained, so shareholders face weaker production expectations even as profit measures improved.
Q3 2026 revenue was $79.5 million, down 5% from $83.4 million in Q3 2025; nine-month revenue was $236.3 million, down 5%.
Q3 2026 Adjusted EBITDA was $26.7 million, up from $20.2 million; net income was $1.7 million versus a $1.9 million loss; basic and diluted EPS was $(0.03), unchanged year over year.
Company now expects 2026 RNG production to be modestly below its guidance range; 2026 Adjusted EBITDA guidance was maintained, with results expected at the lower end of the range.
Three new RNG projects with about 2.0 million MMBtu of annual design capacity are expected to begin commercial operations over 2027.
Quanterix reported third-quarter 2026 revenue of $35.0 million, up 6.3% from the second quarter but down from $40.2 million a year earlier, and a net loss of $21.6 million, compared with $33.5 million a year earlier. The company narrowed its 2026 total revenue outlook to $142-146 million, which gives shareholders a clearer range for the full year.
Q3 2026 revenue of $35.0 million, compared with $40.2 million in Q3 2025 and up 6.3% from Q2 2026.
Net loss of $21.6 million, or $0.46 per share, compared with a net loss of $33.5 million, or $0.73 per share, a year earlier.
2026 total revenue outlook narrowed to $142-146 million; adjusted gross margin expectation of 48-50% unchanged; year-end cash expected at about $70 million with no debt.
Cash, cash equivalents, marketable securities and restricted cash totaled $80.7 million at September 30, 2026.
Uniti Group reported third quarter 2026 revenue of $848.1 million, up from $722.6 million a year earlier, but posted a net loss of $244.5 million, compared with net income of $1,608.9 million in the prior-year quarter that included a $1,685.4 million gain on settlement of preexisting relationships. Adjusted EBITDA was $289.3 million, down from $327.8 million, and the company raised its full-year 2026 revenue outlook to $3.665 billion to $3.695 billion while projecting a net loss of $590 million to $620 million.
Third quarter revenue of $848.1 million, up from $722.6 million in the same quarter of 2025
Net loss of $244.5 million, versus net income of $1,608.9 million in the prior-year quarter, which included a $1,685.4 million settlement gain
Adjusted EBITDA of $289.3 million, down from $327.8 million a year earlier
2026 outlook: revenue of $3.665 billion to $3.695 billion, net loss of $590 million to $620 million, and Adjusted EBITDA of $1.46 billion to $1.49 billion
ADC Therapeutics reported third quarter 2026 results, with net product revenue of $21.0 million, up from $15.8 million a year earlier, and a net loss of $25.3 million, or $0.16 per share, versus $41.0 million, or $0.30 per share, in the prior-year quarter. Cash and cash equivalents were $189.2 million at September 30, 2026, down from $261.3 million at December 31, 2025, and the company said its October 2026 financing restructuring extends its expected cash runway into 2029.
Q3 2026 net product revenue was $21.0 million, compared with $15.8 million in Q3 2025; license revenue and royalties were $0.7 million in both periods.
Q3 2026 net loss was $25.3 million ($0.16 per share), compared with $41.0 million ($0.30 per share) a year earlier; adjusted net loss was $8.8 million.
Cash and cash equivalents were $189.2 million at September 30, 2026, versus $261.3 million at December 31, 2025.
October 2026 restructuring included an $86.6 million PIPE financing, elimination of a $150 million change-of-control payment, and a reduction of the senior secured loan principal by $68.5 million to $50 million.
LKQ Corporation said Salvatore A. Abbate will become President and Chief Executive Officer and join the Board effective November 9, 2026, earlier than the previously announced December 15, 2026 start date. The change ends the interim Office of the CEO led by Chairman John Mendel and Audit Committee Chair Sue Gove, which had overseen operations since October 23, 2026.
Abbate's start date moved from December 15, 2026 to November 9, 2026
Abbate becomes principal executive officer for SEC rules on November 9, 2026
Interim Office of the CEO, Mendel and Gove, which oversaw operations since October 23, concludes
Chairman Mendel said the Board has full confidence in Abbate
Jasper Therapeutics announced the results of its offer to purchase all outstanding warrants issued in its September 18, 2025 underwritten public offering, at $0.324 in cash per warrant, which expired on November 7, 2026. A total of 8,510,658 warrants were properly tendered, about 68.94% of the outstanding warrants, and the company expects to pay $2,757,453.19 in cash for them.
8,510,658 warrants were properly tendered and not withdrawn, about 68.94% of outstanding warrants.
Offer price was $0.324 in cash per warrant, without interest; the offer expired at 12:00 a.m. Eastern Time on November 7, 2026.
The company expects to pay an aggregate of $2,757,453.19 in cash, to be made promptly.
The offer was described in a Schedule TO originally filed with the SEC on October 7, 2026.
Spruce Biosciences reported a third-quarter 2026 net loss of $24.0 million, or $(8.51) per share, up from $8.2 million, or $(14.58) per share, a year earlier. The company also separated its CRHX-101 program into a new subsidiary, Adrenyx Biosciences, and plans to distribute Adrenyx shares to Spruce stockholders, a step its board has not yet approved.
Q3 2026 net loss was $24.0 million, or $(8.51) per share, versus $8.2 million, or $(14.58) per share, in Q3 2025; R&D expenses were $18.1 million.
Cash and cash equivalents were $87.7 million at September 30, 2026, up from $48.9 million at December 31, 2025, which the company says will fund operations and debt obligations into the second half of 2027.
The Distribution of Adrenyx stock is expected in the first half of 2027, but Spruce's board has not yet approved it or set a record date.
Under an amended Avenue loan agreement dated November 6, 2026, up to $15.0 million of Tranche 2 may be drawn between January 1, 2027 and March 31, 2027.
The merger between Mentari Therapeutics and InMed Pharmaceuticals closed on November 9, 2026, and the combined company now trades on the Nasdaq Capital Market as MTRI under the name Mentari Therapeutics, Inc. The closing included private placements with about $490 million in gross proceeds, which the company says provide runway into 2029, and the filing puts outstanding shares at about 58.3 million. The filing contains no revenue, profit, or guidance figures, so the financial effect on shareholders is defined mainly by the new capital and share count.
Private financings totaled about $490 million in gross proceeds, led by Fairmount, including conversion of $50.0 million of previously issued convertible notes plus accrued interest.
About 58.3 million shares of common stock and equivalents are outstanding after the reverse stock split, financings, and merger.
Shares began trading on Nasdaq Capital Market under the ticker MTRI on November 9, 2026.
Todd Shegog joined the Board and will chair the Audit Committee.
Whitehawk Therapeutics reported a third-quarter 2026 net loss of $21.2 million, up from $17.7 million a year earlier, as research and development expenses rose to $18.1 million from $14.3 million. The company reported no revenue in the quarter and said its cash, cash equivalents and short-term investments of $169.7 million should fund operations into the second half of 2028.
Q3 2026 net loss was $21.2 million, compared with $17.7 million in Q3 2025.
Research and development expenses were $18.1 million, compared with $14.3 million a year earlier.
Cash, cash equivalents and short-term investments were $169.7 million as of September 30, 2026, versus $145.7 million at December 31, 2025.
The Phase 1 trial of HWK-206 began in the U.S., and the FDA granted it Fast Track designation; initial Phase 1 data from HWK-007 and HWK-016 are expected in the first half of 2027.
Evolv Technologies named Jason Blessing, age 55, as an independent director effective November 6, 2026, filling a Class III seat until the 2027 annual meeting. He also joins the Audit Committee and the Nominating and Corporate Governance Committee, and the board determined he meets audit committee independence requirements and qualifies as an audit committee financial expert.
Appointed effective November 6, 2026, to serve as a Class III director until the 2027 annual meeting of stockholders
Joins the Audit Committee and the Nominating and Corporate Governance Committee
Previously served as President and CEO of Model N, Inc. from May 2018 to September 2024, and as a Model N director until August 2026
Will receive compensation as a non-employee director under the company's Non-Employee Director Compensation Policy
Delcath Systems reported third-quarter 2026 revenue of $35.1 million, up from $20.6 million a year earlier, and net income of $7.0 million, compared with $0.8 million. The company raised its full-year 2026 revenue guidance to $115 million to $117 million, which signals continued growth in HEPZATO KIT sales for shareholders.
Q3 2026 net income of $7.0 million, or $0.17 diluted per share, versus $0.8 million, or $0.02 per share, in Q3 2025
Q3 2026 HEPZATO KIT revenue of $32.7 million, up from $19.3 million; non-GAAP adjusted EBITDA of $11.5 million, up from $5.3 million
2026 guidance raised to $115 million to $117 million in total revenue, with gross margins of 87% to 89% and positive adjusted EBITDA
Cash and investments of $104.3 million as of September 30, 2026, with no debt
RB Global reported third-quarter 2026 results with revenue up 17% year over year to $1.3 billion and net income up 47% to $140.2 million, helped by a one-time $18.2 million excise tax refund. The company raised its full-year 2026 GTV growth outlook to 14% to 15% from 9% to 11% and narrowed its adjusted EBITDA range to $1,525 million to $1,545 million from $1,495 million to $1,545 million, while also declaring a $0.33 quarterly dividend.
Diluted EPS was $0.70, up 63%; diluted adjusted EPS was $1.03, up 11%
Full-year 2026 GTV growth outlook raised to 14% to 15% from 9% to 11%; adjusted EBITDA low end raised to $1,525 million
Repurchased about 3.9 million shares for $350.0 million in the quarter; $500.0 million remained under the NCIB as of September 30, 2026
Quarterly dividend of $0.33 per share payable December 17, 2026, to holders of record November 25, 2026
CNH Industrial agreed to form a joint venture with Kobelco Construction Machinery by selling a 70% interest in its Construction Equipment business for $700 million in cash, based on an agreed enterprise value of $1 billion. CNH will keep a 30% stake and says it expects to use the net cash proceeds to reduce debt, but the deal requires regulatory approvals and is expected to close by the end of 2027.
Buyers pay $700 million in cash for 70% of the business, valued at an enterprise value of $1 billion, subject to adjustments
CNH retains a 30% interest in the joint venture, with a three-year lock-up period for each party
Closing is expected by the end of 2027; either party may terminate if closing has not occurred by March 30, 2028
CNH said it will report its 2026 third quarter earnings in a separate announcement the same day
Turning Point Brands reported third-quarter 2026 results, with net sales up 27.0% to $151.1 million, driven by growth in its Modern Oral products. Net income attributable to the company fell 81.4% to $3.9 million, and diluted EPS was $0.19 versus $1.13 a year earlier, as sales and marketing spending increased. The company reaffirmed its full-year 2026 guidance, which it had last updated on September 21, 2026.
Net sales rose 27.0% to $151.1 million; Modern Oral net sales rose 102.9% to $74.4 million.
Net income attributable to Turning Point Brands fell 81.4% to $3.9 million; diluted EPS was $0.19 versus $1.13.
Adjusted EBITDA fell 41.3% to $18.4 million, including increased sales and marketing investments.
Full-year 2026 guidance reaffirmed: Modern Oral net sales of $260-$270 million and Adjusted EBITDA of $70-$80 million.
Quanome agreed on November 4, 2026 to acquire 31,579 newly issued shares of QAI Labs, an early-stage, pre-commercial life sciences company, in exchange for 6,541,236 new Quanome common shares, about 19% of its shares outstanding before the issuance. The parties assigned the consideration shares an aggregate value of $5.0 million, which implies an equity valuation of about $100 million for QAI Labs, and the deal is subject to closing conditions. For shareholders, the deal brings new strategic exposure but also meaningful dilution.
Quanome issues 6,541,236 new common shares, about 19% of shares outstanding before issuance and about 15.97% after.
Quanome receives 31,579 QAI Labs shares, an interest of about 5% immediately after issuance.
Aggregate negotiated transaction value is $5.0 million; implied QAI Labs equity valuation is about $100 million.
The agreement can be terminated if closing has not occurred by December 31, 2026, unless the parties agree otherwise.
Orthofix reported third-quarter 2026 net sales of $207.9 million, up 1.1% from $205.6 million a year earlier, and a net loss of $6.1 million, narrowed from $22.8 million. The company lowered its full-year 2026 net sales guidance to $825 million to $830 million from $845 million to $855 million, and its adjusted EBITDA guidance to $86 million to $88 million from $95 million to $98 million, citing weaker U.S. Spine performance.
Q3 2026 net sales were $207.9 million, up 1.1% reported and 2.3% pro forma constant currency; Global Limb Reconstruction rose 8.5% and Spinal Implants, Biologics and Enabling Technologies fell 1.1%.
Q3 net loss was $(6.1) million, or $(0.15) per share, versus $(22.8) million, or $(0.57) per share, a year earlier; adjusted EBITDA was $26.0 million versus $24.6 million.
2026 net sales guidance was cut to $825 million–$830 million; adjusted EBITDA guidance was cut to $86 million–$88 million.
Cash, cash equivalents and restricted cash were $86.9 million at September 30, 2026, down from $104.4 million at June 30, 2026.
WhiteHorse Finance reported third quarter 2026 results for the period ended September 30, 2026, with net investment income of $4.4 million, or $0.207 per share, down from $4.7 million in the prior quarter. Net asset value per share rose to $11.82 from $11.77, and the board declared a $0.25 per share distribution payable January 6, 2027, while the adviser agreed to lower its incentive fee rate to 17.50%.
Net investment income was $4,439 thousand, or $0.207 per share, down 5.2% from $4,681 thousand in Q2 2026; core net investment income rose 2.7% to $4,806 thousand, or $0.224 per share
Net asset value per share increased to $11.82 from $11.77; net realized losses were $3,631 thousand
Quarterly distribution of $0.25 per share payable January 6, 2027 to holders of record as of December 21, 2026; a special distribution of $0.17 per share is payable December 10, 2026
Adviser voluntarily reduced the incentive fee rate from 20.00% to 17.50% for the quarter ending December 31, 2026
Compass Therapeutics reported a third-quarter 2026 net loss of $27.2 million, or $0.15 per share, up from $14.3 million, or $0.08 per share, a year earlier. Higher research and development and general and administrative spending drove the increase, and cash and marketable securities fell to $163 million, which the company says will fund operations into 2028.
Q3 2026 net loss was $27.2 million ($0.15 per share) versus $14.3 million ($0.08 per share) in Q3 2025.
Nine-month net loss was $70.6 million ($0.38 per share) versus $50.8 million ($0.34 per share) a year earlier.
Cash and marketable securities were $163 million at September 30, 2026, down from $209 million at December 31, 2025, with $48 million used in operating activities.
Profound Medical Corp. said its management will take part in the Stifel 2026 Healthcare Conference in New York City on Thursday, November 12, 2026. The filing is a routine event announcement that furnishes a press release and contains no financial results, guidance, or other new business information.
President Richard Fabian is scheduled to present at 8:40 a.m. Eastern Time on November 12, 2026.
The presentation will be broadcast live and archived on the company's website.
CEO Arun Menawat and CFO Matthew Sobczyk will join Fabian for one-on-one investor meetings during the conference.
SiriusXM announced that Board director Anjali Sud, current CEO of Tubi, will become Chief Executive Officer on January 1, 2027, succeeding Jennifer C. Witz, who steps down as CEO and board member at the end of December 31, 2026. Sud's employment agreement sets a $2,600,000 base salary, a target bonus of two times salary, and equity awards including a $10,000,000 sign-on grant, which shareholders can track in the filing.
Anjali Sud, 43, becomes CEO effective January 1, 2027, and will remain on the Board
Sud's employment agreement sets a $2,600,000 base salary and a target bonus equal to two times base salary
Sud's package includes a $10,000,000 sign-on RSU grant and $4,500,000 in time-based and $4,500,000 in performance-based RSUs
Witz will serve as an advisory consultant from January 1, 2027 through December 31, 2027 at $175,000 per month
The Children's Place filed voluntary Chapter 11 petitions on November 8, 2026, in the U.S. Bankruptcy Court for the District of New Jersey, and plans a Section 363 sale of substantially all its assets. Stores and e-commerce sites remain open, but the filing makes substantially all of the company's debt, about $394 million, in default and accelerated, which puts shareholder value at significant risk.
Chapter 11 petitions filed November 8, 2026; sale bids requested by December 9, 2026
About $394 million in outstanding obligations under debt instruments is in default and accelerated as of the petition date
Company plans to seek a senior secured superpriority debtor-in-possession financing, which is not yet agreed
Consulting agreement with Tiger Capital Group, SB360 Capital Partners and GA Retail Solutions for inventory sales has a $34,132,000 expense budget
Former CEO Dr. Andrew Regan, writing on behalf of Corvus Capital Limited, told the Board in a November 5, 2026 letter that Corvus intends to make a non-binding proposal to acquire all outstanding common stock at $2.00 per share, a 96.3% premium on a post-split basis to the November 4, 2026 closing price, absent a Board proposal. The Board intends to form a special committee of independent directors with full authority over the proposal, but the committee has received no definitive terms and has made no decision, and there is no assurance any transaction will result.
Letter dated November 5, 2026, from Dr. Andrew Regan, former CEO, as a significant stockholder, on behalf of Corvus Capital Limited
Proposed price of $2.00 per share, a 96.3% premium to the November 4, 2026 closing price, on a post-split basis
Board intends to form a special committee of independent directors with full authority to consider and vote on the proposal
No definitive terms received and no decision made; the company does not commit to provide updates
CVR Energy will meet potential lenders on November 9, 2026 about a proposed Term Loan B secured credit facility. The lender presentation describes a potential transaction with Marathon Petroleum Corporation to acquire the St. Paul Park and Mandan refineries and related assets for about $4.2 billion, and it is marked as a preliminary draft, so the deal is not yet final.
Lender meeting scheduled for November 9, 2026 for a proposed Term Loan B secured credit facility
Presentation says the ~$4.2 billion acquisition would be funded with ~$1.5 billion senior secured Term Loan B, ~$1.0 billion of other secured debt, and a mix of equity, cash on hand, crude intermediation and an ABL draw
Target assets are the St. Paul Park, Minnesota and Mandan, North Dakota refineries; pro forma LTM Q3'26 EBITDA is ~$1.9 billion, with an implied acquisition multiple of ~3.6x LTM EBITDA
Company expects ~2.0x LTM Q3'26 Debt/EBITDA after the transaction
In the week of November 2 to November 8, 2026, Strategy reported $283.8 million in net proceeds from sales of its MSTR Class A common stock under its at-the-market program, and used $81.9 million of those proceeds to buy 1,036 bitcoin. It also spent $188.3 million repurchasing STRC preferred stock and held $146.2 million in USD Cash as of November 8.
MSTR common stock sales: 2,051,348 shares, $283.8 million net proceeds, with $18.3 billion still available for issuance
Bitcoin: 1,036 bitcoin bought for $81.9 million; aggregate holdings reached 850,364 bitcoin at an average purchase price of $75,456
STRC preferred repurchases: 1,887,464 shares for $188.3 million; $560.3 million remains under the preferred repurchase program
USD Reserve stood at $4.77 billion as of November 8, 2026, after $21.1 million was used for preferred dividends
Future Vision II Acquisition Corp. (FVN) received written notice on November 5, 2026, from Nasdaq confirming it has regained compliance with the minimum public holders requirement for continued listing on the Nasdaq Capital Market. Nasdaq said the matter is now closed, so the company is no longer under this listing deficiency.
Notice received November 5, 2026 from Nasdaq's Listing Qualifications Department
Compliance regained with minimum public holders requirement under Nasdaq Listing Rule 5550(a)(3)
Nasdaq stated the matter is closed; the 8-K was signed by CEO and Director Danhua Xu on November 9, 2026
Strive reported it bought 29 bitcoin between October 31 and November 6, 2026, at an average price of about $75,721 per bitcoin, including fees and expenses. Its bitcoin holdings rose from 43,124 to 43,153 over the period, while cash and cash equivalents fell by $2.8 million to $487.6 million.
Bitcoin purchased: 29 bitcoin at an average price of approximately $75,721 per bitcoin, inclusive of fees and expenses
Bitcoin held rose from 43,124 as of October 30, 2026 to 43,153 as of November 6, 2026
Cash and cash equivalents fell from $490.4 million to $487.6 million over the same period
Effective Common Shares Outstanding were unchanged at 127,331,109; SATS Stock shares rose by 33,141 to 7,036,559
Motorcar Parts of America reported fiscal second-quarter net sales of $169.2 million, down from $221.5 million a year earlier, and operating income of $10.0 million, down from $16.4 million. The company cut its fiscal 2027 net sales guidance to $715 million-$740 million from $780 million-$800 million, citing delayed customer orders, which lowers the outlook for shareholders.
Q2 net sales were $169.2 million versus $221.5 million a year earlier; the company attributed the $37.5 million decline mainly to delayed customer orders and lower tariff pass-throughs.
Q2 operating income was $10.0 million versus $16.4 million; the quarter included $11.1 million of IEEPA tariff refunds.
Six-month net loss was $12.1 million, or $0.64 per share, compared with net income of $893,000 a year earlier.
Fiscal 2027 net sales guidance was revised to $715 million-$740 million from $780 million-$800 million; operating income is estimated at $37 million-$44 million.
CECO Environmental reported third-quarter 2026 revenue of $404.4 million, up 105% from a year earlier, following its June 1, 2026 acquisition of Thermon. The company swung to a GAAP net loss of $2.0 million, though non-GAAP net income rose to $34.3 million. It raised its full-year 2026 orders and free cash flow conversion outlook, kept its revenue and Adjusted EBITDA outlook unchanged, and introduced a 2027 outlook.
Q3 2026 revenue was $404.4 million, up 105%; GAAP net loss was $2.0 million versus net income of $1.5 million a year earlier.
Non-GAAP diluted EPS was $0.60 versus $0.26; Adjusted EBITDA was $70.1 million, up 202%.
2026 orders outlook raised to exceed $2.5 billion from at least $2.0 billion; free cash flow conversion raised to about 100% of Adjusted EBITDA from at least 55%.
2026 revenue ($1.300 billion to $1.375 billion) and Adjusted EBITDA ($200 million to $225 million) outlooks were maintained; 2027 revenue outlook is $2.1 billion to $2.3 billion.
Bicara Therapeutics reported a third-quarter 2026 net loss of $71.2 million, nearly double the $36.3 million loss a year earlier, as research and development and general and administrative costs rose for its pivotal trial and commercial preparation. The company said its $442.3 million in cash and marketable securities should fund operations into the first half of 2029, and it reiterated that topline interim results from the FORTIFI-HN01 pivotal trial are expected in mid-2027.
Net loss was $71.2 million for the quarter ended September 30, 2026, versus $36.3 million a year earlier.
Research and development expenses rose to $56.5 million from $33.0 million; general and administrative expenses rose to $19.2 million from $7.7 million.
Cash, cash equivalents and marketable securities were $442.3 million at September 30, 2026, which the company expects to fund operations into the first half of 2029.
Topline interim results from the FORTIFI-HN01 pivotal trial are expected in mid-2027.
RadNet reported third-quarter 2026 revenue of $638.3 million, up 22.1%, and Adjusted EBITDA of $105.0 million, up 23.8%, both described as records. GAAP net income attributable to common stockholders fell to $4.2 million, or $0.05 per diluted share, from $5.4 million, or $0.07, a year earlier. The company raised its 2026 Imaging Center guidance for revenue, Adjusted EBITDA and free cash flow, and raised Digital Health Adjusted EBITDA guidance.
Q3 2026 revenue was $638.3 million, up from $522.9 million; Adjusted EBITDA was $105.0 million, up from $84.9 million.
GAAP net income attributable to RadNet common stockholders was $4.2 million ($0.05 per diluted share) versus $5.4 million ($0.07) in Q3 2025; adjusted diluted EPS was $0.30 versus $0.24.
Imaging Center guidance raised to $2,385-$2,435 million revenue, $350-$363 million Adjusted EBITDA and $120-$130 million free cash flow.
Digital Health Adjusted EBITDA fell 11.8% to $3.0 million in Q3; cash was $750.6 million at September 30, 2026, and the pending ONRAD acquisition was referenced.
On November 8, 2026, CorMedix agreed to acquire substantially all assets of Heron Therapeutics for $145.0 million in cash, 14,583,333 new CorMedix common shares, earn-out payments of up to $55 million, and royalties. CorMedix entered into a $150 million senior secured term loan with Pharmakon Advisors to help fund the deal, with $75 million expected to be drawn at closing. The share issuance will dilute existing CorMedix shareholders, and closing is expected in the first quarter of 2027, subject to Heron stockholder approval and regulatory clearance.
Upfront consideration is $145.0 million in cash, subject to adjustments, plus 14,583,333 shares of CorMedix common stock.
Earn-outs of up to $55 million are tied to 2028 ZYNRELEF net sales, with a 5.0% royalty on certain product sales above $25.0 million a year in 2027 through 2029.
CorMedix entered into a $150 million Pharmakon term loan and expects to draw $75 million at closing.
Closing is expected in the first quarter of 2027, subject to Heron stockholder approval and HSR clearance; Heron owes a $4.0 million termination fee in certain cases.
Air Industries Group reported results for the three and nine months ended September 30, 2026, in a press release furnished under Item 2.02. Third-quarter net sales rose 41.1% and the company swung to net income from a loss a year earlier, though results include merger-related costs tied to its pending merger with Tenax Aerospace Acquisition, LLC.
Q3 2026 net sales were $14.6 million, up from $10.3 million in Q3 2025; net income was $946,000 versus a net loss of $44,000.
Nine-month net sales were $38.2 million, up 8.7%, and the net loss narrowed to $902,000 from $1.5 million.
Q3 operating costs included $539,000 of stock compensation and merger-related expenses, with $503,000 of merger-related expense.
The company cited October 2026 net sales of about $5.6 million and firm customer orders in backlog of $95.4 million.
Heron Therapeutics agreed on November 8, 2026 to sell substantially all of its assets to CorMedix, with Heron keeping its tax loss carryforwards, cash and CorMedix shares, and exiting its current operations. The deal requires Heron stockholder approval and is expected to close in the first quarter of 2027, and shareholders will hold a company that no longer runs its current business.
Upfront consideration of $145.0 million in cash, subject to adjustments, plus 14,583,333 CorMedix common shares
Up to $55 million in earn-out payments tied to 2028 ZYNRELEF net sales, plus a 5% royalty on certain product sales above $25.0 million in 2027 through 2029
Proceeds will repay all amounts outstanding under the Hercules working capital facility, and Rubric's $35.0 million of convertible notes will be exchanged for CorMedix shares
Requires approval by holders of a majority of Heron common stock; $4.0 million termination fee payable in specified circumstances; expected close in the first quarter of 2027
Popular, Inc. filed an 8-K updating its third-quarter 2026 results after a commercial borrower in the quick service restaurant industry substantially ceased operations and filed for Chapter 11 bankruptcy following the earnings release. The company recognized an additional $38 million provision for credit losses, lowering quarterly net income to $242.4 million from $266.3 million and diluted EPS to $3.83 from $4.21, and it raised its 2026 net charge-off guidance to 90 bps to 95 bps from 80 bps to 90 bps.
Q3 2026 net income of $242.4 million, down $23.9 million from the $266.3 million in the original earnings release.
Diluted EPS of $3.83 versus $4.21 as originally issued; up from $3.14 in the same quarter of 2025.
The company expects an additional fourth-quarter 2026 charge-off on the same relationship.
2026 net charge-off guidance raised to 90 bps to 95 bps from 80 bps to 90 bps; Common Equity Tier 1 ratio of 16.01%, down 5 bps.
ImmunityBio reported third-quarter 2026 net product revenue of $48.7 million, up 53% from a year earlier, and nine-month net product revenue of $143.6 million, up 92%. Net loss attributable to common stockholders rose to $184.6 million for the quarter from $67.3 million, mainly due to non-cash fair value changes in a related-party convertible note, warrant and derivative liabilities after a higher common stock price, along with higher interest expense and operating costs.
Q3 2026 net product revenue was $48.7 million, up 53% year-over-year; nine-month net product revenue was $143.6 million, up 92%.
Q3 2026 net loss attributable to common stockholders was $184.6 million, versus $67.3 million in Q3 2025; basic loss per share was $0.17 versus $0.07.
Nine-month net loss attributable to common stockholders was $1.0 billion, versus $289.5 million a year earlier.
Cash, cash equivalents and marketable securities totaled $334.3 million as of September 30, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.